Note: This column describes the author’s experience with several multiple myeloma treatments. Not everyone will have the same response to treatment. Consult your doctor before…
Myeloma
Her name badge looked so common and ordinary; it was a tiny, plastic square attached to the hem of a pocket on her scrubs. But…
I used to pride myself on my memory. Growing up, I remembered every detail of things that happened. Sometimes I would – very annoyingly —…
I can vividly recall an incident that occurred inside the infusion room one day last November. It was the third hour of a four-hour drip…
The first patient has been dosed in a Phase 2 trial testing an all-oral, triple-combination treatment that includes Cellcentric’s investigational therapy inobrodib in people…
A few weeks ago, I wrote about the annual challenge I face during the season of Lent: the temptation of Thin Mints. The Thin…
Recently, I’ve observed a new type of quietness between my mum and me. It is not the usual silence that arises after a myeloma…
A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The…
I just had my quarterly tuneup and oil change — not for my car, though. For me. Just like a car needs regular maintenance, a…
I had asked my mum a simple question about her lunch, but what came back at me made me question why I had ever decided…
Recent Posts
- EU approves under-the-skin Sarclisa for multiple myeloma
- FDA approves dissolving formulation of leukemia drug nilotinib
- Collaboration to test 2 pancreatic cancer treatments in combination
- The caregiver’s shadow self: Who I am becoming in the margins
- Trial data back glioblastoma treatment’s potential to extend survival
